ZuoYi Technology, a leading domestic medical artificial intelligence system development company, recently announced the successful closing of a RMB 100 million Series B financing. The round was led by Qiming Venture Partners, with participation from well-known investment institutions including Haier Capital.

CEC Capital Group served as the exclusive financial advisor for ZuoYi Technology in this transaction.

The funds from this financing will be used for the research and development upgrade of ZuoYi Technology's diagnostic and therapeutic AI product pipeline, as well as the expansion of related commercial applications.

Founded in 2015, ZuoYi Technology is an innovative enterprise focused on the application of artificial intelligence technology in the medical field. The company integrates the latest AI technologies such as deep learning, big data processing, semantic understanding, and interactive medical dialogue, aiming to create "proactive medical AI." Through technology, ZuoYi Technology aims to expand the supply of high-quality medical resources and alleviate the conflict between excessive concentration of high-quality medical resources and excessive dispersion of patient demand.